Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS8V3L
|
|||
| Drug Name |
Anle138b
|
|||
| Synonyms |
Anle138b; 882697-00-9; Emrusolmin; ANLE-138b; 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1h-pyrazole; Emrusolmin [INN]; E7WRA77JET; 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole; CHEMBL4748063; 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole; 1H-Pyrazole, 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-; Anle 138b; UNII-E7WRA77JET; Anle 138b; Anle-138b; SCHEMBL1660250; SCHEMBL21440048; BCP32558; Anle138b, >=98% (HPLC); BDBM50553260; MFCD30146410; NSC805132; s6782; AKOS037649277; CS-6522; DB13927; NSC-805132; BS-17773; HY-101855; D80685; EN300-331610; A858288; Z2327237898; 3-(1,3-dioxaindan-5-yl)-5-(3-bromophenyl)-1H-pyrazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1 | [1] | |
| Company |
MODAG GmbH
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H11BrN2O2
|
|||
| Canonical SMILES |
C1OC2=C(O1)C=C(C=C2)C3=CC(=NN3)C4=CC(=CC=C4)Br
|
|||
| InChI |
InChI=1S/C16H11BrN2O2/c17-12-3-1-2-10(6-12)13-8-14(19-18-13)11-4-5-15-16(7-11)21-9-20-15/h1-8H,9H2,(H,18,19)
|
|||
| InChIKey |
RCQIIBJSUWYYFU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Synuclein alpha (SNCA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Alzheimer's disease | |||
| Parkinson's disease | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Parkinson disease | |||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Amyloid formation | |||
| WikiPathways | Ectoderm Differentiation | |||
| Parkinsons Disease Pathway | ||||
| Parkin-Ubiquitin Proteasomal System pathway | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04685265) A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Anle138b interaction in alpha-synuclein aggregates by dynamic nuclear polarization NMR. Methods. 2023 Jun;214:18-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.